PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Eperisone→

Eperisone PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
64840-90-0
Molecular formula
C17H25NO
Molecular weight
259.4 g/mol
Drug class
Centrally acting skeletal-muscle relaxantpiperidine derivative
Mechanism of action
Acts on spinal reflex pathways and reduces reflex-mediated skeletal-muscle tone. Experimental work supports depression of spinal reflex activity and effects on voltage-gated sodium/calcium channels; a 2024 study also reported P2X7 antagonism, but the established clinical mechanism remains incompletely elucidated.
Indications / reported uses
  • Improvement of myotonic conditions associated with neck-shoulder-arm syndrome, scapulohumeral periarthritis and low back pain
  • Spastic paralysis associated with selected cerebrovascular, spinal and other neurological disorders in the cited Japanese product information; authorisation varies by country

Sources: Singapore National Drug Formulary — Myonal (eperisone hydrochloride) · PubMed randomised trial in acute musculoskeletal spasm · PubMed mechanism study · Chemical and Pharmaceutical Bulletin (2024; P2X7 study) · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Eperisone PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Eperisone Permitted Daily Exposure (PDE) report (the Eperisone PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Eperisone Occupational Exposure Limit (OEL) report (the Eperisone OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.